• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

by MM360 Staff | Nov 5, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

Caribou’s CB-011 may be effective, safe for hard-to-treat myeloma

by Andrea Lobo | Nov 4, 2025 | Myeloma News

One-time use of CB-011, Caribou Biosciences’ off-the-shelf CAR T-cell therapy candidate, showed a manageable safety profile and resulted in lasting responses in adults with treatment-resistant or relapsed multiple myeloma. That’s according to the first data from the...

Therapy wins rare pediatric disease designation for hard-to-treat glioma

by Marisa Wexler, MS | Nov 4, 2025 | Myeloma News

The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to iopofosine I 131 — now being tested in young people in a clinical trial in North America — as a potential treatment for inoperable relapsed or refractory (hard-to-treat)...

November shines a spotlight on pancreatic cancer awareness

by Marisa Wexler, MS | Nov 4, 2025 | Myeloma News

November is Pancreatic Cancer Awareness Month, and advocates nationwide are hosting events to unite the community and raise awareness about the condition. For this year’s campaign, The National Pancreas Foundation is particularly highlighting the importance of early...

Cero seeking more safety, dosing data on T-cell therapy for AML

by Andrea Lobo | Nov 4, 2025 | Myeloma News

A third dose of CER-1236, Cero Therapeutics’ T-cell therapy candidate for acute myeloid leukemia (AML), was administered to an AML patient taking part in an early clinical trial, with the goal of generating further safety and dosing information. The additional dosing...

by MM360 Staff | Nov 4, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More
« Older Entries
Next Entries »

Recent Content

  • In vivo CAR-T exhibits activity in advanced multiple myeloma
  • FDA backs faster development of new therapy for hard-to-treat AML
  • The efficacy and safety of anti-CD38 monoclonal antibodies in transplant-ineligible newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials
  • Predictive values of baseline 18F-FDG PET/CT for toxicities and outcomes in patients with relapsed or refractory multiple myeloma following BCMA CAR T-cell therapy
  • Correction: Chen et al. The Efficacy and Safety of Tandem Transplant Versus Single Stem Cell Transplant for Multiple Myeloma Patients: A Systematic Review and Meta-Analysis. Diagnostics 2024, 14, 1030
  • Comparison of Standard of Care with or Without a PD-1/PD-L-1 Inhibitor for the Treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials
  • Combo treatment may offer new hope to astrocytoma patients: Trial
  • Reduced-versus Standard-dose Melphalan as Single-agent Conditioning Regimen in Auto HSCT for Multiple Myeloma: A Systematic Review and Meta-Analysis
  • Dosing begins in trial testing Enhertu for ovarian cancer
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT